QurAlis Announces First-in-Human Dose in Phase 1 Clinical Trial of QRL-101, a First-in-Class Kv7 Precision Therapy for ALS
QRL-101 aims to reduce hyperexcitability-induced motor neuron degeneration
CAMBRIDGE, Mass., Jan. 5, 2023 /PRNewswire/ -- QurAlis Corporation, a clinical-stage biotechnology company developing breakthrough precision medicines for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets, today announced that the company recently initiated dosing in a Phase 1 clinical trial of QRL-101 (QRA-244), a first-in-class selective Kv7.2/7.3 ion channel opener for the treatment of hyperexcitability-induced disease progression in ALS.
"We are excited to initiate dosing in this clinical trial of QRL-101, marking our second program to enter the clinic in less than a month," said Kasper Roet, Ph.D., CEO and co-founder of QurAlis. "ALS is one of the most devastating, fatal neurodegenerative diseases and no therapies significantly extend patients' lives. The validity of Kv7.2/7.3 as a drug target for the treatment of ALS comes from research using human ALS motor neurons and is strongly supported by the results of a clinical study published in JAMA Neuro showing that Kv7 modulation can decrease spinal and cortical motor neuron excitability, both of which have been linked to patient survival. QRL-101 has been shown in preclinical studies to have strong potential to control motor neuron hyperexcitability induced excitotoxicity with significantly fewer side effects than other drug candidates. QRL-101 has the potential to be a first-in-class effective therapy for ALS patients suffering from hyperexcitability-induced motor neuron degeneration."
"Motor system hyperexcitability occurs in approximately 50 percent of all ALS patients and is linked to potassium channel dysfunction, recent studies found that the gene coding for the potassium channel Kv7.2 is dysregulated in sporadic ALS," said Leonard H. van den Berg, M.D., Ph.D., professor of neurology and chair, TRICALS. "Previously, targeting these potassium channels in ALS patients showed promising results but that particular drug is no longer available due to side effects experienced in its marketed indication, epilepsy, which is thought to be the result of its non-selective profile. Developing a safer, more selective drug that targets the potassium channel Kv7.2/7.3 is a promising, clinically validated therapeutic strategy and we applaud QurAlis for advancing the QRL-101 program."
This first-in-human Phase 1 study (NCT05667779) is a randomized, double-blind, placebo-controlled, single-ascending-dose, single-site clinical trial designed to evaluate the safety, tolerability, and pharmacokinetics of QRL-101 in adult healthy volunteers. More information about this clinical trial can be found at www.clinicaltrials.gov.
About Amyotropic Lateral Sclerosis (ALS)
About QurAlis Corporation
View original content to download multimedia:https://www.prnewswire.com/news-releases/quralis-announces-first-in-human-dose-in-phase-1-clinical-trial-of-qrl-101-a-first-in-class-kv7-precision-therapy-for-als-301712631.html